ATXI insider filings

AVENUE THERAPEUTICS, INC. — 35 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-01-06. Screen ATXI transaction legs live →

Insider transaction summary — last 90 days

No insider filings (Forms 3/4/5) for ATXI between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.

Recent insider filings — AVENUE THERAPEUTICS, INC.

FiledFormInsiderReported transactionsSource
2026-01-064Fortress Biotech, Inc. — 10% ownerGrant/award (A): 111,209 @ $0EDGAR
2025-04-024Fortress Biotech, Inc. — 10% ownerGrant/award (A): 33,724 @ $0EDGAR
2024-12-034Herskowitz Neil — DirectorSale (S): 23 @ $2EDGAR
2024-11-074KRANZLER JAY D — DirectorSale (S): 61 @ $2.24EDGAR
2024-10-014KRANZLER JAY D — DirectorPurchase (P): 3 @ $2.40 · Purchase (P): 497 @ $2.50EDGAR
2024-09-254Jin David — Interim PFO and COOGrant/award (A): 65,000 @ $0EDGAR
2024-09-254ROSENWALD LINDSAY A MD — DirectorGrant/award (A): 30,000 (derivative) @ $0EDGAR
2024-09-254Oltmans Curtis Gale — DirectorGrant/award (A): 30,000 (derivative) @ $0EDGAR
2024-09-254MacLean Alexandra — Chief Executive Officer, DirectorGrant/award (A): 170,000 @ $0EDGAR
2024-09-254Charles Faith L. — DirectorGrant/award (A): 30,000 (derivative) @ $0EDGAR
2024-09-254Herskowitz Neil — DirectorGrant/award (A): 30,000 (derivative) @ $0EDGAR
2024-09-254KRANZLER JAY D — DirectorGrant/award (A): 30,000 (derivative) @ $0EDGAR
2024-04-174Fortress Biotech, Inc. — 10% ownerGrant/award (A): 413,507 @ $0EDGAR
2024-01-034Fortress Biotech, Inc. — 10% ownerGrant/award (A): 2,101,496 @ $0EDGAR
2023-12-134Davidow Robert L — 10% ownerSale (S): 264,000 @ $0.14 · Sale (S): 18,000 @ $0.15 · Sale (S): 61,000 @ $0.14 · Sale (S): 126,000 @ $0.14 · Sale (S): 128,000 @ $0.14 · Sale (S): 20,000 @ $0.14EDGAR
2023-09-124ROSENWALD LINDSAY A MD — DirectorPurchase (P): 348,675 @ $0.72EDGAR
2023-09-124Fortress Biotech, Inc. — 10% ownerPurchase (P): 418,410 @ $0.72EDGAR
2023-07-054Charles Faith L. — DirectorGrant/award (A): 100,000 (derivative) @ $0EDGAR
2023-07-054Jin David — Interim PFO and COOGrant/award (A): 250,000 (derivative) @ $0EDGAR
2023-07-054ROSENWALD LINDSAY A MD — DirectorGrant/award (A): 100,000 (derivative) @ $0EDGAR
2023-07-054Oltmans Curtis Gale — DirectorGrant/award (A): 100,000 (derivative) @ $0EDGAR
2023-07-054Herskowitz Neil — DirectorGrant/award (A): 100,000 (derivative) @ $0EDGAR
2023-07-054KRANZLER JAY D — DirectorGrant/award (A): 100,000 (derivative) @ $0EDGAR
2023-07-034MacLean Alexandra — Chief Executive Officer, DirectorGrant/award (A): 800,000 (derivative) @ $0EDGAR
2023-04-044Fortress Biotech, Inc. — 10% ownerGrant/award (A): 52,419 @ $0EDGAR
2023-01-044Fortress Biotech, Inc. — 10% ownerGrant/award (A): 90,909 @ $0 · Grant/award (A): 231,316 @ $0EDGAR
2022-10-134InvaGen Pharmaceuticals, Inc. — 10% ownerSale (S): 388,888 @ $7.71EDGAR
2021-12-214Oltmans Curtis Gale — DirectorGrant/award (A): 49,020 @ $0EDGAR
2021-12-214Herskowitz Neil — DirectorGrant/award (A): 49,020 @ $0 · Grant/award (A): 20,000 @ $0EDGAR
2021-12-214KRANZLER JAY D — DirectorGrant/award (A): 49,020 @ $0 · Grant/award (A): 20,000 @ $0EDGAR
2021-12-204Vazzano Joseph Walter — Chief Financial OfficerGrant/award (A): 100,505 @ $0EDGAR
2021-12-204Lu Lucy — President, CEO, DirectorGrant/award (A): 411,616 @ $0EDGAR
2021-09-154Vazzano Joseph Walter — Chief Financial OfficerSale (S): 7,160 @ $1.62EDGAR
2021-05-074Herskowitz Neil — DirectorPurchase (P): 2,500 @ $3.99EDGAR
2020-08-214Vazzano Joseph Walter — Chief Financial OfficerSale (S): 3,840 @ $12.13EDGAR

Recent 8-K events — AVENUE THERAPEUTICS, INC.

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2026-02-238-K1.01 — Entry into a Material Definitive Agreement
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2025-12-318-K5.07 — Submission of Matters to a Vote of Security HoldersEDGAR
2025-11-188-K?
8.01 — Other Events
EDGAR
2025-11-128-K1.01 — Entry into a Material Definitive Agreement
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2025-04-308-K1.01 — Entry into a Material Definitive Agreement
1.02 — Termination of a Material Definitive Agreement
2.01 — Completion of Acquisition or Disposition of Assets
9.01 — Financial Statements and Exhibits
EDGAR
2025-03-178-K3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingEDGAR
2025-03-078-K8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2024-11-298-K3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingEDGAR
2024-11-148-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2024-09-278-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
9.01 — Financial Statements and Exhibits
EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=ATXI returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs